Researchers from the University of Virginia School of Medicine and Inova Health System have received seed grant funding from the Integrated Translational Health Research Institute of Virginia (iTHRIVE) to study a new biomarker for hereditary angioedema (HAE). iTHRIVE is awarding up to $50,000 to early-phase research projects…
A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…
Europe’s umbrella organization for 800 rare disease associations has developed a sweeping initiative to help the continent’s 30 million rare disease patients and their caregivers learn about their conditions, find assistance and receive treatment. Eurordis-Rare Diseases Europe hopes to improve the current piecemeal treatment and support program with a holistic,…
People with hereditary angioedema appear to have a higher risk of developing non-alcoholic fatty liver disease, even before receiving angioedema medicines that affect liver function, a new study suggests. Researchers recommend that these patients undergo continuous monitoring to detect and manage fatty liver disease in its early stages. The…
People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those of their caregivers. But most lawmakers aren’t experts in even one well-known disease — let alone the world’s estimated 7,000 rare disorders. So how does the…
Treatment with Takhzyro (lanadelumab) effectively reduces the number of attacks in patients with hereditary angioedema even in early phases of treatment, new analysis of data from the Phase 3 HELP study shows. Most recent trial results were shared in a poster, “Lanadelumab demonstrates rapid and sustained prevention of hereditary…
The unique mode each specific compound binds to and blocks the enzyme plasma kallikrein could lead to the development of improved therapies for patients with hereditary angioedema (HAE), according to a new study. The research, “Structures of full-length plasma kallikrein bound to highly specific inhibitors describe…
KalVista Pharmaceuticals‘ investigational therapy KVD900 for the treatment of hereditary angioedema (HAE) rapidly reduces the activity of plasma kallikrein, one of the drivers of HAE attacks. That promising result comes from the first-in-human Phase 1 clinical trial of KVD900, and was shared at the 11th C1 Inhibitor Deficiency…
RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…
Daily treatment with BCX7353, an investigative oral inhibitor of plasma kallikrein by BioCryst Pharmaceuticals, was well-tolerated and lowered attack rates in hereditary angioedema (HAE) patients included in a Phase 3 trial. Both 110 mg and 150 mg doses provided a significant benefit by decreasing HAE attacks — the APeX-2 trial’s primary…
Get regular updates to your inbox.
